Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Col

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
The American Journal of Cardiology|March 15, 1996
Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapyK W Mahaffey, C B Granger, R Collins, et al.
Circulation|July 1, 1992
Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplaseF W Bär, F W Verheugt, J Col, et al.
Journal of the American College of Cardiology|September 14, 2000
Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK?A K Jacobs, J K French, J Col, et al.
Journal of the American College of Cardiology|September 14, 2000
Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?J Slater, R J Brown, T A Antonelli, et al.
Lancet (London, England)|January 30, 1988
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplastyM L Simoons, A E Arnold, A Betriu, et al.
Circulation|March 15, 1995
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I InvestigatorsK L Lee, L H Woodlief, E J Topol, et al.
Circulation|March 1, 1996
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trialC B Granger, J Hirsch, R M Califf, et al.
European Heart Journal|November 10, 2000
Lack of progress in cardiogenic shock: lessons from the GUSTO trialsV Menon, J S Hochman, A Stebbins, et al.
Journal of the American College of Cardiology|March 1, 1996
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trialL K Newby, R M Califf, A Guerci, et al.
Journal of the American College of Cardiology|October 3, 2006
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesMarc Cohen, Kenneth W Mahaffey, Karen Pieper, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
The American Journal of Cardiology|March 15, 1996
Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapyK W Mahaffey, C B Granger, R Collins, et al.
Circulation|July 1, 1992
Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplaseF W Bär, F W Verheugt, J Col, et al.
Journal of the American College of Cardiology|September 14, 2000
Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded coronaries for Cardiogenic shocK?A K Jacobs, J K French, J Col, et al.
Journal of the American College of Cardiology|September 14, 2000
Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?J Slater, R J Brown, T A Antonelli, et al.
Lancet (London, England)|January 30, 1988
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplastyM L Simoons, A E Arnold, A Betriu, et al.
Circulation|March 15, 1995
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I InvestigatorsK L Lee, L H Woodlief, E J Topol, et al.
Circulation|March 1, 1996
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trialC B Granger, J Hirsch, R M Califf, et al.
European Heart Journal|November 10, 2000
Lack of progress in cardiogenic shock: lessons from the GUSTO trialsV Menon, J S Hochman, A Stebbins, et al.
Journal of the American College of Cardiology|March 1, 1996
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trialL K Newby, R M Califf, A Guerci, et al.
Journal of the American College of Cardiology|October 3, 2006
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromesMarc Cohen, Kenneth W Mahaffey, Karen Pieper, et al.
Pageof 7